MARKET

AVXL

AVXL

Anavex Life
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.42
+0.14
+1.24%
After Hours: 11.42 0 0.00% 16:00 05/18 EDT
OPEN
11.44
PREV CLOSE
11.28
HIGH
11.90
LOW
11.31
VOLUME
766.48K
TURNOVER
--
52 WEEK HIGH
28.70
52 WEEK LOW
3.600
MARKET CAP
799.84M
P/E (TTM)
-25.1320
1D
5D
1M
3M
1Y
5Y
Anavex Life Sciences Reports Narrower-Than-Expected Fiscal Q2 Loss
MT Newswires · 5d ago
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 5d ago
Anavex Life Sciences Q2 EPS $(0.12) Beats $(0.14) Estimate
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is unchanged from the same period last year.
Benzinga · 5d ago
Anavex Life Sciences EPS beats by $0.03
Anavex Life Sciences (AVXL): FQ2 GAAP EPS of -$0.12 beats by $0.03.Cash and cash equivalents at March 31, 2021 of~ $75.9M, sufficient cash runway for up to three (3) years.Press
Seekingalpha · 5d ago
Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...
GlobeNewswire · 5d ago
Anavex Life Sciences Posts Narrower-Than-Expected Q2 Loss
MT Newswires · 5d ago
Earnings Scheduled For May 13, 2021
  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Benzinga · 5d ago
Why Anavex Life Sciences (AVXL) Might Surprise This Earnings Season
Zacks.com · 05/11 12:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVXL. Analyze the recent business situations of Anavex Life through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVXL stock price target is 18.10 with a high estimate of 25.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 125
Institutional Holdings: 22.54M
% Owned: 32.19%
Shares Outstanding: 70.04M
TypeInstitutionsShares
Increased
35
5.01M
New
21
980.69K
Decreased
20
512.39K
Sold Out
11
166.04K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/President/Chief Executive Officer/Secretary/Director
Christopher Missling
Chief Financial Officer/Treasurer
Sandra Boenisch
Senior Vice President
Adebayo Laniyonu
Lead Director/Independent Director
Claus van der Velden
Independent Director
Peter Donhauser
Independent Director
Elliot Favus
Independent Director
Athanasios Skarpelos
Independent Director
Steffen Thomas
No Data
  • All
  • Financials
  • Insiders
More
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.

Webull offers kinds of Anavex Life Sciences Corp stock information, including NASDAQ:AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.